HUTCHMED (China) Limited (HCM) has announced it will receive a milestone payment following the approval and market launch of FRUZAQLA (fruquintinib) 1mg/5mg capsules in Japan by its partner, Takeda (TAK). This product targets patients with previously treated metastatic colorectal cancer. Approval for the manufacturing and marketing of FRUZAQLA was granted by the Japanese Ministry of Health, Labour and Welfare.
In September 2024, Takeda confirmed it received authorization from the Japanese Ministry of Health, Labour and Welfare to manufacture and sell FRUZAQLA Capsules 1mg/5mg. These capsules are a selective oral inhibitor of the vascular endothelial growth factor receptor (VEGFR) -1, -2, and -3. They are designed for the treatment of advanced or recurrent colorectal cancer (CRC), which is neither curable nor resectable, and has progressed following chemotherapy.
